Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, ß-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin. It also provides fat-soluble vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products, as well as animal nutrition products. In addition, the company offers injectable levofloxacin lactate, vancomycin hydrochloride injection, and injectable teicoplanin products. The company was incorporated in 1997 and is headquartered in Shaoxing, China.
Research context
Zhejiang Medicine Co., Ltd appears in PyInvesting’s Shanghai Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Zhejiang Medicine Co., Ltd is currently in a long term uptrend where the price is trading 1.4% above its 200 day moving average.
From a valuation standpoint, the stock is 80.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.9.
Zhejiang Medicine Co., Ltd's total revenue rose by 9.6% to $2B since the same quarter in the previous year.
Its net income has increased by 144.0% to $193M since the same quarter in the previous year.
Finally, its free cash flow fell by 28.5% to $83M since the same quarter in the previous year.
Based on the above factors, Zhejiang Medicine Co., Ltd gets an overall score of 4/5.